user
menu
letter
Sign InRegister
langEnglisharrow

VEGF: Cutting off tumor's feeding channel

Not only vascular endothelial growth factor (VEGF) plays a role in promoting angiogenesis and regeneration, but shows multiple functions such as immune regulation and neuroprotection. VEGF family members exert their effects through interactions with a family of three VEGF receptors. VEGF is overexpressed in many tumors, leading to its upregulation as a key driver of angiogenesis. Therefore, it becomes a hot target of drug development for tumors.
Currently, there are more than 100 antibody drugs, such as monoclonal antibodies (mAb) and bispecific antibodies (BsAb) against VEGF are widely-used for clinical treatment.
Given its significant role in solid tumors, intraocular neovascular disorders, and certain cardiovascular diseases, there is no surprise that VEGF has been heavily studied for new target therapeutics.
ACROBiosystems has developed a variety of VEGF proteins with different molecules, subtypes, species, and tags to help expedite your antibody drug development. All SPR&BLI protocols are available for free.

Product list

VEGF-A
VEGF-B
VEGF-C
VEGF-D
VEGF R1
VEGF R2
VEGF R3
Cat. No.MoleculeProduct DescriptionOrder Now
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order
Order

Product Features

High purity verified by MALS
High purity verified by MALS
The purity of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) is more than 95% in HP-SEC, and the molecular weight of this protein is around 40-55 kDa verified by SEC-MALS.
High bioactivity validated by ELISA&SPR&BLI&cell based assay
>>ELISA
High purity verified by MALS

Immobilized Human VEGF R1&VEGF R2, Fc Tag at 2 μg/mL (100 μL/well) can bind Human VEGF165, His Tag (Cat. No. VE5-H5248) with a linear range of 0.004-0.063 μg/mL (QC tested).

Request Protocol

High purity verified by MALS

Immobilized Human VEGF165, premium grade (MALS verified) (Cat. No. VE5-H4210) at 0.1 μg/mL (100 μL/well) can bind Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) with a linear range of 1.2-10 ng/mL (QC tested).

Request Protocol

>>SPR
High purity verified by MALS

Immobilized Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) on CM5 Chip via Streptavidin, can bind Avastin with an affinity constant of 0.417 nM as determined in SPR assay (Biacore T200) (Routinely tested).

Request Protocol

>>BLI
High purity verified by MALS

Loaded Avastin (Bevacizumab) on AHC Biosensor, can bind Human VEGF165, His Tag (Cat. No. VE5-H5248) with an affinity constant of 0.448 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Request Protocol

>>Cell based assay
High purity verified by MALS

ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 4.216-9.281 ng/mL (Routinely tested).

Request Protocol

High purity verified by MALS

Inhibition assay shows that the proliferation effect of ActiveMax® Human VEGF165, Tag Free (MALS verified) (Cat. No. VE5-H4210) is inhibited by increasing concentration of anti-VEGF mAb (Avastin). The concentration of VEGF165 used is 20 ng/mL. The ED50 is 0.065-0.229 μg/mL (Routinely tested).

Request Protocol

Citations

FAQ

Q

What are the differences among VEGF-A, VEGF-B, VEGF-C, and VEGF-D when selecting a recombinant protein?

VEGF family members differ in receptor preference and biological function. VEGF-A primarily activates VEGFR1 and VEGFR2 and is widely used in angiogenesis and anti-VEGF drug studies. VEGF-B mainly signals through VEGFR1, while VEGF-C and VEGF-D are commonly studied in VEGFR3-associated lymphangiogenesis and tumor metastasis. ACROBiosystems offers VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGFR1–3 proteins, enabling researchers to select matched ligand–receptor pairs for pathway-specific binding and inhibitor-screening assays.
Q

How should I choose among VEGF165, VEGF121, and VEGF110 proteins?

VEGF165 is the predominant VEGF-A isoform and is commonly selected for angiogenesis studies, receptor-binding assays, and HUVEC proliferation assays. VEGF121 lacks the heparin-binding region found in VEGF165 and is more freely diffusible, making it useful when extracellular matrix association may affect the assay. VEGF110 is a shorter, proteolytically generated form that can support studies focused on the VEGF receptor-binding region. The appropriate molecule depends on the biological context, assay format, and required interaction properties.
Q

Which VEGF165 tag format should I choose for SPR, BLI, ELISA, or cell-based assays?

Choose the VEGF165 format according to the assay. Tag-free VEGF165 is suitable for cell-based functional assays to minimize potential tag interference. His-tagged VEGF165 supports convenient capture and detection in ELISA and BLI. Avitag™-biotinylated VEGF165 enables controlled immobilization on streptavidin-coated surfaces for SPR, BLI, and ELISA. FITC-labeled VEGF165 is suitable for fluorescence-based binding assays.
Q

When should I choose human, mouse, rat, or cynomolgus monkey VEGF and VEGFR proteins?

Species selection should reflect the experimental model and development stage. Human proteins are commonly used for immunization, therapeutic antibody screening, and human receptor-binding studies. Mouse and rat proteins support preclinical disease models, while cynomolgus monkey proteins are useful for evaluating cross-species binding before non-human primate studies. Using species-matched VEGF ligands and receptors can reduce uncertainty caused by sequence and affinity differences, while cross-species protein panels can help assess candidate cross-reactivity.
Q

How can ACRO’s VEGF products support an anti-VEGF inhibitor-screening workflow?

Researchers can combine recombinant VEGF ligands, VEGFR1–3 receptor proteins, biotinylated proteins, VEGF165-coupled magnetic beads, and a VEGFA–VEGFR2 inhibitor-screening ELISA kit across different stages of screening. Binding assays such as ELISA, SPR, and BLI can be used to identify and characterize candidates, followed by HUVEC proliferation and inhibition assays to confirm functional activity. ACRO’s VEGF165 model has also been validated using bevacizumab as a reference antibody, providing an established benchmark for anti-VEGF screening workflows.
  • Background
  • Product list
  • Product Features
  • Citations
  • FAQ